United States Biotechnology & Medical Research

Inozyme Pharma Inc (INZY)

Track

Ticker: INZY Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Inozyme Pharma Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 2 Apr 2025
Value US$1,700,714.78 | Price 443.55 | Shares 68,656 (+6.4%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-04-03 2025-04-02 S Sale
2.4
Treco Douglas A

CEO & Chairman

Executive Director
68,656 +6.4%
443.55
US$1,700,715 		68,656 +6.4% 443.55 US$1,700,715
2024-04-03 2024-04-02 S Sale
2.4
Treco Douglas A

CEO

Executive Director
83,971 +45.9%
110.57
US$4,462,279 		83,971 +45.9% 110.57 US$4,462,279
2023-08-03 2023-08-01 B Purchase
2.5
Hopfner Robert Lorne
Non-Executive Director
32,186 -13.8%
377.63
US$2,280,660 		32,186 -13.8% 377.63 US$2,280,660
2023-08-03 2023-08-01 B Purchase
2.5
Hopfner Robert Lorne
Non-Executive Director
119,048 +4.2%
4.80
US$571,430 		119,048 +4.2% 4.80 US$571,430
2023-08-03 2023-08-01 B Purchase
1.3
Pivotal bioVenture Partners Fund I, L.P.
Non-Executive Director
714,285 +83.3%
4.80
US$3,428,568 		714,285 +83.3% 4.80 US$3,428,568
2023-08-03 2023-08-01 B Purchase
1.3
Pivotal bioVenture Partners Fund I, L.P.
Non-Executive Director
119,048 +4.2%
4.80
US$571,430 		119,048 +4.2% 4.80 US$571,430
2023-05-15 2023-05-12 B Purchase
2.5
Hopfner Robert Lorne
Non-Executive Director
228,702 +6.7%
6.25
US$1,429,388 		228,702 +6.7% 6.25 US$1,429,388
2023-05-15 2023-05-11 B Purchase
2.5
Hopfner Robert Lorne
Non-Executive Director
219,230 +6.8%
6.48
US$1,420,610 		219,230 +6.8% 6.48 US$1,420,610
2023-03-30 2023-03-29 B Purchase
2.5
Hopfner Robert Lorne
Non-Executive Director
344,592 +12.0%
4.54
US$1,563,724 		344,592 +12.0% 4.54 US$1,563,724
2023-03-29 2023-03-28 B Purchase
2.5
Hopfner Robert Lorne
Non-Executive Director
156,766 +5.8%
4.16
US$652,335 		156,766 +5.8% 4.16 US$652,335
2023-03-29 2023-03-27 B Purchase
2.5
Hopfner Robert Lorne
Non-Executive Director
51,074 +1.9%
3.70
US$188,729 		51,074 +1.9% 3.70 US$188,729
2022-12-19 2022-12-15 B Purchase
3.4
Bjarke Henric Bjorn

SVP, COO

Officer
21,500 +25.6%
1.39
US$29,885 		21,500 +25.6% 1.39 US$29,885
2022-04-21 2022-04-19 B Purchase
2.9
Longitude Capital Partners III, LLC
Large shareholder
1,355,000 +48.1%
3.69
US$4,999,950 		1,355,000 +48.1% 3.69 US$4,999,950
2022-04-20 2022-04-19 B Purchase
Bolte Axel

Chief Executive Officer

Executive Director
67,750 +35.5%
3.69
US$249,998 		67,750 +35.5% 3.69 US$249,998
2022-04-20 2022-04-19 B Purchase
0.5
Subramanian Sanjay

SVP, CFO

Officer
27,100 +inf%
3.69
US$99,999 		27,100 +inf% 3.69 US$99,999
2022-04-20 2022-04-19 B Purchase
1.3
Pivotal bioVenture Partners Fund I, L.P.
Non-Executive Director
1,070,000 +67.2%
3.69
US$3,948,300 		1,070,000 +67.2% 3.69 US$3,948,300
2022-04-20 2022-04-19 B Purchase
2.5
Hopfner Robert Lorne
Non-Executive Director
1,070,000 +67.2%
3.69
US$3,948,300 		1,070,000 +67.2% 3.69 US$3,948,300
2022-04-20 2022-04-19 B Purchase
3.4
Bjarke Henric Bjorn

SVP, COO

Officer
27,100 +50.6%
3.69
US$99,999 		27,100 +50.6% 3.69 US$99,999
2021-06-25 2021-06-24 S Sale
Bolte Axel

Chief Executive Officer

Executive Director
66,788 -25.9%
0.00
US$7 		66,788 -25.9% 0.00 US$7
2021-02-01 2021-01-28 S Sale
2.3
Novo Holdings A/S
Large shareholder
375,000 -14.6%
21.00
US$7,875,000 		375,000 -14.6% 21.00 US$7,875,000
2020-07-29 2020-07-28 B Purchase
2.3
Novo Holdings A/S
Large shareholder
375,000 +17.1%
16.00
US$6,000,000 		375,000 +17.1% 16.00 US$6,000,000
2020-07-29 2020-07-28 B Purchase
2.4
Sanofi
Large shareholder
81,250 +18.5%
16.00
US$1,300,000 		81,250 +18.5% 16.00 US$1,300,000
2020-07-28 2020-07-28 B Purchase
2.5
Hopfner Robert Lorne
Non-Executive Director Large shareholder
187,500 +13.4%
16.00
US$3,000,000 		187,500 +13.4% 16.00 US$3,000,000
2020-07-28 2020-07-28 B Purchase
2.4
SANDELL SCOTT D
Large shareholder
250,000 +11.4%
16.00
US$4,000,000 		250,000 +11.4% 16.00 US$4,000,000
2020-07-28 2020-07-28 B Purchase
2.1
MAKOWER JOSHUA
Large shareholder
250,000 +11.4%
16.00
US$4,000,000 		250,000 +11.4% 16.00 US$4,000,000
2020-07-28 2020-07-28 B Purchase
2.5
Sofinnova Venture Partners X, L.P.
Large shareholder
437,500 +27.5%
16.00
US$7,000,000 		437,500 +27.5% 16.00 US$7,000,000
2020-07-28 2020-07-28 B Purchase
1.3
Pivotal bioVenture Partners Fund I, L.P.
Large shareholder
187,500 +13.4%
16.00
US$3,000,000 		187,500 +13.4% 16.00 US$3,000,000
2020-07-28 2020-07-28 B Purchase
2.8
Rock Springs Capital Management LP
Large shareholder
24,000 +2.3%
16.00
US$384,000 		24,000 +2.3% 16.00 US$384,000
2020-07-28 2020-07-28 B Purchase
2.8
Rock Springs Capital Management LP
Large shareholder
576,000 +123.1%
16.00
US$9,216,000 		576,000 +123.1% 16.00 US$9,216,000
2020-07-28 2020-07-28 B Purchase
2.7
Florence Anthony A. Jr.
Large shareholder
250,000 +11.4%
16.00
US$4,000,000 		250,000 +11.4% 16.00 US$4,000,000
2020-07-28 2020-07-28 B Purchase
2.5
BASKETT FOREST
Large shareholder
250,000 +11.4%
16.00
US$4,000,000 		250,000 +11.4% 16.00 US$4,000,000
2020-07-28 2020-07-28 B Purchase
3.0
New Enterprise Associates 15, L.P.
Large shareholder
250,000 +11.4%
16.00
US$4,000,000 		250,000 +11.4% 16.00 US$4,000,000
2020-07-28 2020-07-28 B Purchase
2.1
Sonsini Peter W.
Large shareholder
250,000 +11.4%
16.00
US$4,000,000 		250,000 +11.4% 16.00 US$4,000,000
2020-07-28 2020-07-28 B Purchase
2.9
Makhzoumi Mohamad
Large shareholder
250,000 +11.4%
16.00
US$4,000,000 		250,000 +11.4% 16.00 US$4,000,000
2020-07-28 2020-07-28 B Purchase
2.9
Longitude Capital Partners III, LLC
Large shareholder
625,000 +28.5%
16.00
US$10,000,000 		625,000 +28.5% 16.00 US$10,000,000
2020-07-28 2020-07-28 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
600,000 +42.7%
16.00
US$9,600,000 		600,000 +42.7% 16.00 US$9,600,000
Explore more

More insider trading research around Inozyme Pharma Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America